this is ectreme undervalued.
Agenus Inc. (including its subsidiaries, also referred to as “Agenus,” the .... presenting at least three product candidates at .... Society of Clinical Oncology, or ASCO ( ASCO 2015 Conquer Cancer Foundation )
CEO " With Partner Novasep Will Commence Commerical Manufacturing of MYDICAR" LINK
24 Mar 2015
Pompey, France, and San Diego, CA, USA, March 24, 2015
“We are very pleased to have a partner with Novasep to prepare for and commence commercial manufacturing of MYDICAR drug substance,” said Dr. Krisztina Zsebo, CEO of Celladon. “Novasephas demonstrated technical excellence and a real commitment to helping advance the MYDICAR program.” Less
gotta feel for em
Jaffray Downgrades CYBR $54 Target on Next Qt Earnings LINK
Jaffray Note Shaking Cyber Security
“In Q4, CYBR had net results of -16 percent, so Q1 was a modest improvement. For Q2, 67 percent of rsellers expect normal seasonality $54 target
LOL common sense
That's Correct. Another $12+ Gain On That Upcoming Upgrade.